Cover Image
市場調查報告書

Sucampo Pharmaceuticals, Inc.:產品平台分析

Sucampo Pharmaceuticals, Inc. - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 199804
出版日期 內容資訊 英文 46 Pages
訂單完成後即時交付
價格
Back to Top
Sucampo Pharmaceuticals, Inc.:產品平台分析 Sucampo Pharmaceuticals, Inc. - Product Pipeline Review - 2014
出版日期: 2014年04月28日 內容資訊: 英文 46 Pages
簡介

本報告提供Sucampo Pharmaceuticals, Inc.的治療藥開發平台現狀及各開發階段比較分析,為您彙整藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Sucampo Pharmaceuticals, Inc.的基本資料

Sucampo Pharmaceuticals, Inc.概要

  • 主要資訊
  • 企業資料

Sucampo Pharmaceuticals, Inc.:R&D概要

  • 主要的治療範圍

Sucampo Pharmaceuticals, Inc.:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

Sucampo Pharmaceuticals, Inc.:開發中產品概況

  • 後期開發中產品
    • 登記前的產品/聯合治療模式
    • 申請未受理的/被撤消的產品/聯合治療模式
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式

Sucampo Pharmaceuticals, Inc.:藥物簡介

  • lubiprostone
  • unoprostone isopropyl
  • SPI-017
  • cobiprostone
  • SPI-3608

Sucampo Pharmaceuticals, Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Sucampo Pharmaceuticals, Inc.:最近的開發平台趨勢

Sucampo Pharmaceuticals, Inc.:暫停中的計劃

Sucampo Pharmaceuticals, Inc.:企業發表

Sucampo Pharmaceuticals, Inc.:總公司和子公司的所地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC04825CDB

Global Markets Direct's, 'Sucampo Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the Sucampo Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Sucampo Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Sucampo Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Sucampo Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Sucampo Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

  • Evaluate Sucampo Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Sucampo Pharmaceuticals, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Sucampo Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Sucampo Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Sucampo Pharmaceuticals, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Sucampo Pharmaceuticals, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Sucampo Pharmaceuticals, Inc. Snapshot
    • Sucampo Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • Sucampo Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Sucampo Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Sucampo Pharmaceuticals, Inc. - Pipeline Products Glance
    • Sucampo Pharmaceuticals, Inc. - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Filing rejected/Withdrawn Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Sucampo Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Sucampo Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Sucampo Pharmaceuticals, Inc. - Drug Profiles
    • lubiprostone
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • unoprostone isopropyl
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SPI-017
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cobiprostone
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SPI-3608
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Sucampo Pharmaceuticals, Inc. - Pipeline Analysis
    • Sucampo Pharmaceuticals, Inc. - Pipeline Products by Target
    • Sucampo Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
    • Sucampo Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
    • Sucampo Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • Sucampo Pharmaceuticals, Inc. - Recent Pipeline Updates
  • Sucampo Pharmaceuticals, Inc. - Dormant Projects
  • Sucampo Pharmaceuticals, Inc. - Company Statement
  • Sucampo Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Sucampo Pharmaceuticals, Inc., Key Information
  • Sucampo Pharmaceuticals, Inc., Key Facts
  • Sucampo Pharmaceuticals, Inc. - Pipeline by Indication, 2014
  • Sucampo Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014
  • Sucampo Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014
  • Sucampo Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2014
  • Sucampo Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2014
  • Sucampo Pharmaceuticals, Inc. - Pre-Registration, 2014
  • Sucampo Pharmaceuticals, Inc. - Filing rejected/Withdrawn, 2014
  • Sucampo Pharmaceuticals, Inc. - Phase III, 2014
  • Sucampo Pharmaceuticals, Inc. - Phase II, 2014
  • Sucampo Pharmaceuticals, Inc. - Phase I, 2014
  • Sucampo Pharmaceuticals, Inc. - Preclinical, 2014
  • Sucampo Pharmaceuticals, Inc. - Pipeline by Target, 2014
  • Sucampo Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2014
  • Sucampo Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2014
  • Sucampo Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2014
  • Sucampo Pharmaceuticals, Inc. - Recent Pipeline Updates, 2014
  • Sucampo Pharmaceuticals, Inc. - Dormant Developmental Projects,2014
  • Sucampo Pharmaceuticals, Inc., Subsidiaries

List of Figures

  • Sucampo Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2014
  • Sucampo Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014
  • Sucampo Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014
  • Sucampo Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2014
  • Sucampo Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2014
  • Sucampo Pharmaceuticals, Inc. - Pipeline by Top 10 Route of Administration, 2014
  • Sucampo Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2014
  • Sucampo Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top